Research graph
References from Efficacy of house dust mite allergen immunotherapy in allergic rhinitis: a network meta-analysis based on component-resolved classification. Local targets link to admitted publications; unresolved targets remain external evidence.
Worsening of chronic house-dust-mite-induced respiratory allergies: an observational survey in three European countries
10.1016/j.waojou.2021.100563 · 2021 · External reference
Allergen immunotherapy: past, present and future
10.1038/s41577-022-00786-1 · 2023 · External reference
Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis
10.1111/all.13201 · 2017 · External reference
Allergen manufacturing and quality aspects for allergen immunotherapy in Europe and the United States: an analysis from the EAACI AIT Guidelines Project
10.1111/all.13357 · 2018 · External reference
House dust mite allergens: new discoveries and relevance to the allergic patient
10.1007/s11882-016-0649-y · 2016 · External reference
Quality requirements for allergen extracts and allergoids for allergen immunotherapy
10.1016/j.aller.2017.09.002 · 2017 · External reference
Varying allergen composition and content affects the in vivo allergenic activity of commercial Dermatophagoides pteronyssinus extracts
10.1159/000337654 · 2012 · External reference
Dermatophagoides pteronyssinus proteins and their role in the diagnostics and management of house dust mite allergy: exploring allergenic components
10.5114/ada.2024.142390 · 2024 · External reference
Comparison of the allergenic potency of house dust extract and house dust mite allergen extract for subcutaneous allergen immunotherapy
10.1248/bpb.b18-00710 · 2019 · External reference
EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis
10.1111/all.13317 · 2018 · External reference
Allergen immunotherapy on the way to product-based evaluation-a WAO statement
10.1186/s40413-015-0078-8 · 2015 · External reference
EAACI guidelines on allergen immunotherapy: executive statement
10.1111/all.13420 · 2018 · External reference
Improvement of the therapeutic management of allergic patients in Europe – an expert think tank’s position paper on allergen immunotherapy
10.1016/j.waojou.2025.101109 · 2025 · External reference
Molecular profile clustering of IgE responses and potential implications for specific immunotherapy
10.1097/aci.0b013e3283630ca5 · 2013 · External reference
Molecular diagnosis for allergen immunotherapy
10.1016/j.jaci.2018.12.1021 · 2019 · External reference
Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy
10.1016/j.jaci.2020.03.029 · 2020 · External reference
Specific IgE against the house dust mite allergens Der p 5, 20 and 21 influences the phenotype and severity of atopic diseases
10.1111/all.15553 · 2023 · External reference
360° approach to the patient with mite allergy: from scientific evidence to clinical practice
10.3389/falgy.2024.1298816 · 2024 · External reference
Allergen immunotherapy (AIT): a prototype of Precision Medicine
10.1186/s40413-015-0079-7 · 2015 · External reference
Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model
10.1111/all.14575 · 2021 · External reference
Efficacy of subcutaneous and sublingual immunotherapy for house dust mite allergy: a network meta-analysis-based comparison
10.1016/j.jaip.2021.08.018 · 2021 · External reference
Pharmacotherapy and immunotherapy of allergic rhinitis induced by house dust mite, grass, and birch pollen allergens: a meta-analysis of randomized clinical trials
10.1080/17476348.2023.2241364 · 2023 · External reference
Subcutaneous versus sublingual immunotherapy for adults with allergic rhinitis: a systematic review with meta-analyses
10.1002/lary.29586 · 2022 · External reference
Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range
10.1177/0962280216669183 · 2018 · External reference
Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range
10.1186/1471-2288-14-135 · 2014 · External reference
Hierarchy and molecular properties of house dust mite allergens
10.1016/j.alit.2015.05.004 · 2015 · External reference
Elucidating the allergen composition of therapeutic allergen products (Abstract 712)
10.1111/all.15095 · 2021 · External reference
Improved quality control of allergen products: assessing the molecular allergen composition by mass spectrometry
10.1111/all.16339 · 2024 · External reference
Treatment and prevention of house dust mite allergies
2023 · External reference
Limited impact of Der p 23 IgE on treatment outcomes in tablet allergy immunotherapy phase III study
10.1111/all.14200 · 2021 · External reference
Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy
10.1016/j.jaci.2018.10.048 · 2019 · External reference
Broad immunogenicity of house dust mite proteins contrasts restricted specific IgE and IgG4 associated with allergy
10.1371/journal.pone.0338593 · 2026 · External reference
Molecular reactivity profiling upon immunotherapy with a 300 IR sublingual house dust mite tablet reveals marked humoral changes towards major allergens
10.1111/all.15327 · 2022 · External reference
Efficacy of house dust mite immunotherapy in Chinese allergic rhinitis patients with diverse sensitization patterns: a multicenter study (COVER Study)
10.1111/all.70072 · 2026 · External reference
RoB 2: a revised tool for assessing risk of bias in randomised trials
10.1136/bmj.l4898 · 2019 · External reference
Automating network meta-analysis
10.1002/jrsm.1054 · 2012 · External reference
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
10.1016/j.jclinepi.2010.03.016 · 2011 · External reference
Bias in meta-analysis detected by a simple, graphical test
10.1136/bmj.315.7109.629 · 1997 · External reference
Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study
10.1159/000327566 · 2012 · External reference
Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial
10.1186/s13601-017-0180-9 · 2017 · External reference
Subcutaneous allergen immunotherapy in adults allergic to house dust mites: a phase 3 randomized controlled trial
10.1111/all.70063 · 2025 · External reference
A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses
10.1016/s0091-6749(05)80208-8 · 1990 · External reference
Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double‐blind, randomized, placebo‐controlled trial
10.1046/j.1365-2222.2003.01735.x · 2003 · External reference
Changes in CD4+CD25+FoxP3+ regulatory T cells and serum cytokines in sublingual and subcutaneous immunotherapy in allergic rhinitis with or without asthma
10.1159/000503143 · 2020 · External reference
A large scale multicentre randomized, placebo-controlled subcutaneous house dust mite allergen immunotherapy (HDM SCIT) in allergic rhinitis: MITAR Study
10.12932/ap-221123-1735 · 2024 · External reference
Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis
10.1016/j.jaci.2013.11.012 · 2014 · External reference
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial
10.1016/j.jaci.2015.06.036 · 2016 · External reference
Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial
10.1016/j.jaci.2016.06.044 · 2016 · External reference
House dust mite sublingual tablet is effective and safe in patients with allergic rhinitis
10.1111/all.12996 · 2017 · External reference
Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite–induced allergic rhinitis
10.1016/j.jaci.2016.09.043 · 2017 · External reference
Efficacy and safety of SQ house dust mite sublingual immunotherapy‐tablet in Japanese children
10.1111/all.13544 · 2018 · External reference
Efficacy of house dust mite sublingual tablet in the treatment of allergic rhinoconjunctivitis: A randomized trial in a pediatric population
10.1111/pai.12984 · 2019 · External reference
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial
10.1016/j.jaci.2020.07.036 · 2021 · External reference
Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): a randomised, double-blind, placebo-controlled, phase III trial
10.1016/j.lanepe.2024.101136 · 2025 · External reference
Efficacy and safety of sublingual versus subcutaneous immunotherapy in children with allergic rhinitis: a systematic review and meta-analysis
10.3389/fimmu.2023.1274241 · 2023 · External reference
House dust mite sublingual immunotherapy for allergic rhinoconjunctivitis: comprehensive review and meta-analytical evidence
10.1159/000551015 · 2026 · External reference
Efficacy and safety of house dust mite sublingual immunotherapy tablets in allergic rhinitis: A systematic review and meta-analysis
10.1016/j.waojou.2022.100691 · 2022 · External reference
